Active substanceCocarboxylaseCocarboxylase
Similar drugsTo uncover
  • Cocarboxylase
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Cocarboxylase
    lyophilizate w / m 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase-Ferein
    lyophilizate w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cocarboxylase-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
  • Cocarboxylase hydrochloride
    lyophilizate w / m in / in 
  • Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
    Composition:

    Active substance: cocarboxylase hydrochloride - 0.025 g or 0.050 g;

    Excipients: sodium carbonate.

    Description:

    Lyophilized dry porous hygroscopic mass of white or almost white color, with a weak specific odor.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.11.D.A   Vitamin B1

    Pharmacodynamics:

    Cocarboxylase, a co-enzyme of thiamine (vitamin B1), is phosphorylated in the body to form mono-, di-, and tri-phosphoric esters, and is a component of enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids. Exogenous vitamin B1 (thiamine) to participate in these processes must be metabolized by phosphorylation into cocarboxylase, a ready-made form of coenzyme. It should be noted that the properties of cocarboxylase are only partially adequate to those of thiamine; cocarboxylase is not used for the prevention and treatment of hypo- and avitaminosis B1.

    Indications:

    Cocarboxylase-Ferein is prescribed in the complex therapy of hepatic and renal insufficiency, diabetic precoma and coma, diabetic ketoacidosis, chronic heart failure and cardiac rhythm disturbances, peripheral neuritis.

    Children prescribe the drug for the same indications. In neonates, the drug is also used in complex therapy of conditions associated with hypoxia and acidosis, including asphyxia of newborns, hypoxic encephalopathy, circulatory insufficiency, pneumonia, sepsis, etc.

    Contraindications:

    Hypersensitivity to the drug.

    Dosing and Administration:

    Cocarboxylase-Ferein is administered intramuscularly or intravenously (either by jet or by drip). The contents of the ampoule (0.025 or 0.05 g) are dissolved immediately before administration to 2 ml of water for injection.With intravenous jet injection, the volume is adjusted to 10-20 ml, with dropwise administration up to 200-400 ml, adding an isotonic sodium chloride solution or a solution of glucose.

    When heart diseases are prescribed for OD-0.2 g per day for 15-30 days. In diabetes (ketoacidosis, coma), the daily dose is 0.1 g. In acute renal and hepatic insufficiency, intravenously jet 0.1-0.15 g 3 times a day or drip (5 % glucose solution) to 0.1-0.15 g per day. With peripheral neuritis, intramuscularly administered at a dose of 0.05-0.1 g per day for 1-1.5 months.

    Children are given intramuscularly, intravenously (drip or jet). Depending on the severity of the condition and clinical symptoms appointed from 0.025 to 0.050 grams per day. The course of treatment is from 3-7 to 15-30 days. The newborn is injected intravenously (slowly) 10 mg per 1 kg of body weight once a day.

    Side effects:

    Allergic reactions are possible (hives, itching); when intramuscular injection - hyperemia, edema at the injection site.

    Interaction:

    Kokarboksilaza enhances the effect of cardiac glycosides and improves their tolerability.

    Form release / dosage:

    Liofilizate for the preparation of solution for intravenous and intramuscular injection.

    Packaging:Ampoules of 0,025 g or 0,050 g complete with a solvent (water for injection) or separately.
    Storage conditions:

    In a place protected from light and inaccessible to children, at a temperature not exceeding +20 FROM.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N002252 / 01-2003
    Date of registration:01.08.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up